NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
STATISTICAL ANALYSIS PLAN 
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b 
Clinical Stud~ to Assess the Efficacy, Safety and Tolerability of8-Week Regimens of 
Novexatin , 10% Topical Solution (Taro Pharmaceuticals, USA, Inc.) in Patients 
with Mild to Moderate Onychomycosis 
3/21/2018 Protocol Number: NVXT 1404 
Novum Study Number: 71442603 
Sponsor: 
Taro Pharmaceuticals U.S.A., Inc. 
3 Skyline Drive, 
Hawthorne, NY 10532 
USA 
Contract Research Organization: 
Novum Pharmaceutical Research Services 
225 W. Station Square Drive, Suite 200 
Pittsburgh, PA 15219 
March 21,2018 
Final Version 3.0 
• Taro Pharmaceuticals U.S.A., Inc. • Page I of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404171442603 
SAP FINAL VERSION APPROVALS 
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group. Multi-Site Phase 2b 
Clinical Stud~ to Assess the Efficacy. Safety and Tolerability of 8-Week Regimens of 
Novexatin . I 0% Topical Solution (Taro Pharmaceuticals, USA. Inc.) in Patients 
with Mild to Moderate Onychomycosis 
Written By: ~ 
Signature:-----------­
Jianhua Liu, MSc 
Senior Biostatistician 
Novum Pharmnceutica I Research Services 
Reviewed By: 
Signature: --:-="-:fjr-¥--'-'-t-----­
Pina D'Angelo, 
Executive Directo cientific Affairs (Biostatistics) 
Novum Pharmaceutical Research Services 
Approved By: 
Signature: #Yt~o~tlorsilf 
Natalie Yantovskiy 
Senior Director, Clinical Research 
Taro Pharmaceuticals U.S.A., Inc. Date:_<J_Cf.:_:_{ 0_3_,:./_W~f ~-
Date: .2 April 2010 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 2 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
Revision History 
Draft 1.0 March 20, 2017 
Draft 2.0 December 12, 2017 
Final 1.0 February 26, 2018 
Final2.0 March 1, 2018 
Final 3.0 March 21, 2018 New Document 
Incorporate Novum's comments 
Add additional analyses, incorporate client 
comments and finalize SAP 
Add summary table T14.3.1 0 Summary of 
Frequency of Evaluation ofToenail 
Condition/Appearance 
Incorporate client's comments 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Jianhua Liu 
Jianhua Liu 
Jianhua Liu 
Jianhua Liu 
Jianhua Liu 
Page 3 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
List of Abbreviations and Definition of Terms 
ADaM 
AE 
ANCOVA 
BP c 
CRF 
CDISC 
CRO 
F 
FDA 
HR 
Hg 
ICF 
ICH 
IND 
ITT 
LOCF 
MedDRA 
OGD 
pp 
SAE 
SAP 
SAS 
SDTM 
USA 
3/21/2018 Analysis Data Model 
Adverse Event 
Analysis of Covariance 
Blood Pressure 
Celsius 
Case Report Form 
Clinical Data Interchange Standards Consortium 
Contract Research Organization 
Fahrenheit 
Food and Drug Administration 
Heart Rate 
Mercury 
Informed Consent Form 
International Conference on Harmonization 
Investigational New Drug 
Intent-to- Treat 
Last Observation Carried Forward 
Medical Dictionary for Regulatory Activities 
The Office of Generic Drugs 
Per-Protocol 
Serious Adverse Event 
Statistical Analysis Plan 
Statistical Analysis System 
Study Data Tabulation Model 
United States of America 
• Taro Pharmaceuticals U.S.A., Inc. • Page 4 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
TABLE OF CONTENTS 
I. INTRODUCTION ....................................................................................................................... 8 
2. OBJECTIVES .............................................................................................................................. 8 
3. OVERALL STUDY DESIGN ..................................................................................................... 8 
4. RANDOMIZATION AND BLINDING .................................................................................... l2 
5. SAMPLE SIZE .......................................................................................................................... 12 
6. STUDY ENDPOINTS ............................................................................................................... 13 
7. STUDY POPULATIONS .......................................................................................................... l4 
8. STATISTICAL ANALYSIS METHODS ................................................................................. l4 
8.1 Baseline Characteristics ...................................................................................................... 14 
8.1.1 Patient Disposition ...................................................................................................... 14 
8.1.2 Demographic and Other Baseline Characteristics ....................................................... 15 
8.1.3 Medical History ........................................................................................................... l5 
8.1.4 Concomitant Medications ........................................................................................... 15 
8.2 Efficacy Analyses ................................................................................................................ IS 
8.2.1 Efficacy Analyses on Primary and Secondary Endpoints .......................................... .15 
8.2.2 Treatment-by-Site Interaction and Pooling of Clinical Sites ...................................... 17 
8.2.3 Additional Analyses .................................................................................................... 17 
8.3 Safety Analysis ............................................................................................................... l8 
8.3.1 Adverse Events ............................................................................................................ l8 
8.3.2 Vital Signs ................................................................................................................... I9 
8.3.3 Clinical Laboratory Results ......................................................................................... l9 
8.3.4 Application Site Reactions .......................................................................................... l9 
8.3 .5 Evaluation of Toenail Condition/ Appearance: ............................................................ 19 
8.4 Multiple Co1nparisons ......................................................................................................... 20 
8.5 Methods for Handling Missing Data ................................................................................... 20 
8.6 Interim Analyses ................................................................................................................. 20 
8.7 Changes to the Protocol Defined Statistical Analysis Plan ................................................. 21 
9. TABLE, LISTING AND FIGURE SHELLS ............................................................................ 21 
Tables for Report Body ............................................................................................................. 23 
Table I Nu1nber ofPatients ................................................................................................. .23 
Table II Summary of Patient Disposition .............................................................................. 24 
Table III Summary of Protocol Deviations ......................................................................... 25 
Table IV Summary of Patients Excluded from Efficacy Analysis ...................................... 26 
Table V Summary of Superiority Analysis Results of Primary Efficacy Endpoint 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure 
Visits) (Intent-to- Treat Population- Observed Case Analysis) ........................................ 27 
Table VI Sensitivity Analysis # 1: Superiority Analysis Results of Primary Efficacy 
Endpoint (Proportion of Patients with Complete Therapeutic Cure at the Test-of-
Cure Visits) (Intent-to-Treat Population) ........................................................................... 28 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 5 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
Table VII Sensitivity Analysis #2: Superiority Analysis Results of Primary Efficacy 
Endpoint (Proportion of Patients with Complete Therapeutic Cure at the Test-of-
Cure Visits) (Intent-to- Treat Population) ........................................................................... 29 
Table VIII Summary of Adverse Events (Safety Population) ............................................... 30 
Tables for section 14 ................................................................................................................. 31 
T14.1.1 Summary ofPatients Included in Analysis Population by Study Center .................... 31 
T14.1.2.1 Summary ofDemographic Data (Safety Population) ............................................. .32 
T14.1.2.2 Summary ofDemographic Data (Intent-to-Treat Population) .................................. 33 
T14.2.1 Summary of Superiority Analysis Results of Primary Efficacy Endpoint Using 
Canfield Evaluation (Proportion of Patients with Complete Therapeutic Cure at 
the Test-of-Cure Visits) (Intent-to-Treat Population- Observed Case Analysis) ............. 34 
T14.2.2 Sensitivity Analysis # 1: Superiority Analysis Results of Primary Efficacy 
Endpoint Using Canfield Evaluation (Proportion of Patients with Complete 
Therapeutic Cure at the Test-of-Cure Visits) (Intent-to-Treat Population) ....................... 35 
T14.2.3 Sensitivity Analysis #2: Superiority Analysis Results ofPrimary Efficacy 
EndpointUsing Canfield Evaluation (Proportion of Patients with Complete 
Therapeutic Cure at the Test-of-Cure Visits) (Intent-to-Treat Population) ....................... 36 
T14.2.4.1 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-! 
(Proportion ofPatients with Complete or Almost Complete Therapeutic Cure at 
the Test-of-Cure Visits) (Intent-to-Treat Population- Observed Case Analysis) ............. 37 
T14.2.4.2 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-1 
Using Canfield Evaluation (Proportion of Patients with Complete or Almost 
Complete Therapeutic Cure at the Test-of-Cure Visits) (Intent-to- Treat Population 
-Observed Case Analysis) ............................................................................................... .38 
T14.2.5 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-2 
(Proportion of Patients with Mycologic Cure at the Test-of-Cure Visits) (Intent-
to-Treat Population- Observed Case Analysis) ................................................................ 39 
Tl4.2.6.1 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-3 
(Proportion of Patients with Complete Clinical Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population -Observed Case Analysis) .................................................... 40 
T14.2.6.2 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-3 
Using Canfield Evaluation (Proportion of Patients with Complete Clinical Cure at 
the Test-of-Cure Visits) (Intent-to-Treat Population- Observed Case Analysis) ............ .41 
T14.2.7.1 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-4 
(Proportion of Patients with Satisfactory Clinical Cure at the Test-of-Cure Visits) 
(Intent-to-Treat Population- Observed Case Analysis) ................................................... .42 
T14.3.1.1 Summary ofFrequency of All Adverse Events by Body System: Day I to 
Day 141 ± 7 (Safety Population) ...................................................................................... 43 
Tl4.3.1.2 Summary ofFrequency of All Adverse Events by Body System: Day 1 to 
Day 365 ± 14 (Safety Population) .................................................................................... 43 
Tl4.3.2 Summary of Frequency of All Adverse Events by Relationship (Safety 
Population) ........................................................................................................................ .44 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 6 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
T14.3.3 Summary of Frequency of All Adverse Events by Severity (Safety 
Population) ......................................................................................................................... 45 
T14.3.4 Summary ofFrequency of Serious Adverse Events (Safety Population) ................... 46 
Tl4.3.5 Summary of Vital Signs (Safety Population) ............................................................. 47 
T14.3.6 Summary of Clinical Laboratory Testing (Hematology) (Safety Population) ........... .48 
T14.3.7 Summary of Clinical Laboratory Testing (Chemistry) (Safety Population) .............. .48 
T14.3.8 Summary of Clinical Laboratory Testing (Urinalysis) (Safety Population) ............... .48 
T14.3.9 Summary ofFrequency of Application Site Reactions (Safety Population) ............... 49 
Tl4.3.10 Summary ofFrequency ofEvaluation ofToenail Condition/Appearance 
(Safety Population) ..................................................................... , ...................................... 50 
L 16.2.1 Listing of Discontinued Patients .................................................................................. 51 
L 16.2.2 Listing of Protocol Deviations ..................................................................................... 52 
Ll6.2.3 Listing of Patients Excluded from the Analysis Population ........................................ 53 
L16.2.4.1 Listing ofDemographic Data ............................................................. , .................... 54 
Ll6.2.4.2 Listing of Medical History .................................................................... ,. ................. 55 
L16.2.4.3 Listing of Concomitant Medication .......................................................................... 56 
L16.2.5 Listing ofDiary Entries and Study Compliance .......................................................... 57 
L 16.2.6.1 Listing of Investigator Clinical Assessment ............................................................. 58 
L16.2.6.2.1 Listing oflnvestigator Visual Assessment (Percent Nail Involvement of 
the Target Toenai\) ............................................................................................................. 59 
Ll6.2.6.2.2 Listing of Canfield Assessment (Percent Nail Involvement of the Target 
Toenail) .. , ........................................................................................................................... 59 
L16.2.6.3 Listing ofKOH Wet Mount & Mycological Culture ............................................... 60 
Ll6.2.6.4 Listing oflnvestigator & Patient Evaluation Of Toenail Appearance & 
Condition ............................................................................................................................ 61 
L 16.2.6.5.1 Listing of Efficacy Endpoints (Observed Case) .................................................... 62 
L16.2.6.5.2 Listing of Efficacy Endpoints Using Canfield Evaluation .................................... 62 
Ll6.2.6.5.3 Listing of Primary Efficacy Endpoints (Sensitivity Analysis) .............................. 63 
Ll6.2.7.1 Listing of Adverse Events by treatment group ......................................................... 64 
Ll6.2.7.2 Listing of Application Site Reactions ....................................................................... 65 
Ll6.2.7.3 Listing of Abnormal Physical Examination Results ................................................. 66 
L 16.2. 7.4 Listing of Positive Pregnancy Test Results .............................................................. 67 
Ll6.2.8.1 Listing of Clinical Laboratory Testing Results (Hematology) ................................. 68 
Ll6.2.8.2 Listing of Clinical Laboratory Testing Results (Chemistry) .................................... 68 
Ll6.2.8.3 Listing of Clinical Laboratory Testing Results (Urinalysis) .................................... 68 
L16.2.8.4 Listing of Vital Signs ................................................................................................ 69 
10. APPENDICES ......................................................................................................................... 70 
Appendix A: Evaluation of Toenail Condition/appearance ...................................................... 70 
Appendix B: Application Site Reactions .................................................................................. 71 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 7 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
1. INTRODUCTION 
This Statistical Analysis Plan (SAP) is based on the final Clinical Study Protocol NVXT 1404 
(Novum Study No. 71442603) Rev. 2 dated July 8, 2016. The SAP provides details on the 
planned statistical methodology for the analysis of the study data. The SAP also outlines the 
statistical programming specifications for the tables, listings and figures. 
This SAP describes the study endpoints, derived variables, anticipated data transformations and 
manipulations, and other details of the analyses not provided in the study protocol. This SAP 
therefore outlines in detail all other aspects pertaining to the planned analyses and 
presentations for this study. 
The following documents were reviewed in preparation of this SAP: 
• Final Clinical Study Protocol NVXT 1404 (Novum Study No. 71442603) Rev. 2 dated 
July 8, 2016 
• Casebook for Novum Study No. 71442603 dated 11/30/2017 
The reader of this SAP is encouraged to also read the clinical protocol for details on the 
conduct of this study, and the operational aspects of clinical assessments and timing for 
completing a patient in this study. 
2. OBJECTIVES 
I. Determine the rates of complete therapeutic cure ofNovexatin® I 0% topical solution (Taro 
Pharmaceuticals, USA) after daily dosing for one 8-week treatment period (Treatment 
Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment 
Group B), and Placebo (vehicle) topical solution (Taro Pharmaceuticals, USA) after two 8-
week treatment periods separated by a 32-week rest period (Treatment Group C), at three 
test-of-cure visits (Day 141, Day 281 and Day 365) in patients with mild to moderate distal 
subungual onychomycosis of the target toenail. 
2. Compare rates of complete therapeutic cure between Treatment Groups according to a 
hierarchical evaluation scheme detailed in the statistical sections. 
3. Evaluate safety and tolerability of the two regimens of Novexatin® 10% topical solution 
(Treatment Groups A and B) in patients with mild to moderate distal subungual 
onychomycosis of the target toenail. 
3. OVERALL STUDY DESIGN 
This randomized, placebo-controlled, double-blind, parallel-group, multi-site study is designed 
to evaluate and compare the efficacy and safety of two dosing regimens ofNovexatin® 10% 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 8 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
topical solution (Taro Pharmaceuticals USA) for the treatment of mild to moderate distal 
subungual onychomycosis of the target toenail. Additionally the active formulation in these 
regimens will be assessed for superiority to a placebo topical solution. 
Up to 180 eligible patients with distal subungual onychomycosis who meet all the inclusion 
criteria and none of the exclusion criteria will be randomized into the study at Visit 2. Patients 
must be at least 18 years of age, in overall good health. They should have a current diagnosis of 
distal subungual onychomycosis of mild-moderate severity. Before any study-specific 
procedures are performed all patients will read and sign the IRE-approved informed consent 
form. 
At least 60 qualified patients in each treatment group will receive randomized and blinded study 
product. The randomization scheme will be 1: I: 1 (Active Treatment A: Active Treatment B: 
Placebo C). The study products are: 
Test: Novexatin® 10% Topical Solution (Taro Pharmaceuticals, USA) 
Placebo: Placebo (Vehicle) Topical Solution (Taro Pharmaceuticals, USA) 
Patients will be assigned to one of the three treatment groups: 
Treatment Group A: Test treatment for Days I -56 and Placebo treatment for 
Days 28I -336 
Treatment Group B: Test treatment for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo treatment for Days I-56 and Days 28I-336 
Treatment and study durations will be as follows: 
Study Duration: 365 days (52 weeks) 
Patients will undergo evaluation for clinical and mycological cure of onychomycosis at the 7 
clinic visits as per study schematic. Randomized patients who withdraw from the study will not 
be replaced. The study will be conducted according to the following schedule: 
Visit Schedule: 
• Visit 1: Days -35 to -I (Screening) 
• Visit 2: Day I (Baseline and Randomization I I st Treatment start) 
• Visit 3: Day 57± 4 (I st Treatment completion) 
• Visit 4: Day I41 ± 7 (Interim) 
• Visit 5: Day 281 ± 14 (2nd Treatment start) 
• Visit 6: Day 337 ± I4 (2nd Treatment completion) 
• Visit 7: Day 365 ± 14 (4 weeks post-treatment) 
Unscheduled visits will be allowed as deemed necessary by Investigator. 
3/21/20I8 • Taro Pharmaceuticals U.S.A., Inc. • Page 9 of7I 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
The primary efficacy endpoint is the proportion of patients in each treatment group with a 
complete therapeutic cure of onychomycosis of the target toenail assessed at each of the two test­
of-cure visits (Day 141 and Day 365). The safety profile of each treatment group will be 
evaluated by comparing adverse events, application site reactions, monitoring vital signs and 
changes in clinical laboratory results obtained throughout the study. 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 10 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
Figure 1 Study Schematic 
PROCEDURE 
Day 
Informed Consent 
Inclusion/ Exclusion Criteria Review 
Demographics 
Medical History 
Physical Examination 
Vital Signs 
KOH test 
Fungal Culture collection 
Clinical Lab Tests 
Target Nail trimming (if needed) 
before nail involvement/appearance 
assessments 
Target toenail involvement (assessed 
by visual assessment)* 
Planimetry Assessment 
Evaluation of toenail 
condition/appearance (by patient and 
investigator) 
Investigator Clinical Assessment 
Urine Pregnancy Test** 
Dispense study product, supplies 
Dispense Diary/Instructions 
Application site reactions 
Collect unused/empty bottle 
Collect and Review Patient Diary 
Adverse Event Assessments 
Concomitant Medication Review 
Schedule next visit Visit I 
-35to-1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X Visit 2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X Visit 3 
57±4 
(Week 
8) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X Visit 4 
141 ± 7 
(Wecl\ 20) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X Visit 5 
281 ± 14 
(Wccl\ 
40) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
* At Visit I, both toena!ls wtll be assessed if a btlateralmfectlon of the btg toenalls are present. 
**All women of childbearing potential 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Visit 6 
337 ± 14 
(Week 
48) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X Visit 7 
365 ± 14 
(Weel\ 52) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Page 11 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
4. RANDOMIZATION AND BLINDING 
The study product will be packaged and blinded by an independent clinical packaging company. 
The randomization will be generated in blocks of 3, containing the study products in three 
configurations: 
A. bottles #1 & 2-Test and bottles #3 & 4-Placebo 
B. bottles #1 & 2-Test and bottles #3 & 4-Test 
C. bottles #1 & 2-Placebo and bottles #3 & 4-Placebo. 
Three patients worth of study product bottles 1 & 2 will be packed into a larger box. This larger 
box will be designated "one block" of study product. The study product bottles I & 2 will be 
blinded, packaged and delivered to the study site in blocks at the beginning of the enrollment. 
Bottles 3 & 4 will be delivered to the study site before Visit 5 (211d treatment start). 
At each Visit 2 and Visit 5 each patient will receive two 5 ml bottles of study product according 
to the randomization code. Patients will be randomized to a treatment regimen in a blinded 
fashion by assigning randomization numbers in ascending sequential order starting with the 
lowest available randomization number at each site. All patients randomized will be identified by 
initials, date of birth, and a unique six-digit patient number. The first two-digits will identify the 
Investigator site where the patient was enrolled and the last four will correspond with the 
randomization number of study product bottle assigned to the patient. A perforated or two-part 
label will be attached to each of the small sized boxes of study product supplies. Both pieces of 
the label will include the following information: Protocol number, randomization number, space 
for patient's initials, statement that the study product is for investigational usc only, space for 
dispensing date and the Sponsor's name. In addition all patients will be provided with written 
instructions on how to use the study product. One part of the label shall remain attached to the 
box. The other part will be removed prior to dispensing and attached to the study product log. 
The Investigator, staff at the study site, study monitors, and data analysis/management personnel 
will be blinded to the patient assignment. 
At the end of the study, after all the clinical data has been entered and the study database has 
been locked, a copy of the randomization will be sent to the statistician. 
5. SAMPLE SIZE 
The primary statistical analysis of interest is a comparison ofthe rates of therapeutic cure (as 
defined by "clinical cure" AND "mycological cure") ofNovexatin® 10% topical solution to the 
rate oftherapeutic cure of placebo in the Intent-to-Treat Population (ITT). The rate oftherapeutic 
cure for the Novexatin® 10% topical solution 8-week regimens is expected to be approximately 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 12 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404171442603 
49%. The rate of therapeutic cure for placebo is expected to be approximately 21%. 
Approximately 46 patients in each treatment group in the ITT population will provide over 80% 
power to show a difference at p < 0.05 (two-sided Z test and a pooled response rate for the 
standard error of the difference in proportions) between each of the active treatment groups and 
the placebo group. To allow for a 23% drop-out rate, a total of 180 patients will be enrolled in 
the study, with up to 60 patients in each of the treatment groups. 
6. STUDY ENDPOINTS 
Primary Endpoint: 
The proportion of patients in each treatment group with a complete therapeutic cure of 
onychomycosis of the target toenail assessed at each of the two test-of-cure visits (Day 141 and 
Day 365). 
Secondary Endpoints: 
1. The proportion of patients in each treatment group with a complete or almost complete 
therapeutic cure of onychomycosis of the target toenail assessed at each of the two test­
of-cure visits (Day 141 and Day 365). 
2. The proportion of patients in each treatment group with a mycological cure of the target 
toenail assessed at each of the two test-of-cure visits (Day 141 and Day 365). 
3. The proportion of patients in each treatment group with a complete clinical cure ofthe 
target toenail assessed at each ofthree test-of-cure visits (Day 141, Day 281 and Day 
365). 
4. The proportion of patients in each treatment group with a satisfactory clinical cure of the 
target toenail assessed at each of three test-of-cure visits (Day 141, Day 281 and Day 
365). 
Complete therapeutic cure is defined as both complete clinical and mycological cure ofthe 
target toenail 
Almost complete therapeutic cure is defined as both mycological and satisfactory clinical cure 
of the target toenail 
Mycological cure is defined as a negative KOH test and a negative fungal culture. 
Complete clinical cure is defined as 0% nail involvement. 
Satisfactory clinical cure is defined as~ 5% of the target toenail involvement. 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 13 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
7. STUDY POPULATIONS 
Intent-to- Treat (ITT) Population 
• All randomized patients who applied at least one dose of assigned study product 
• Had a positive mycological culture screening (Visit 1) 
The primary analyses will be conducted on the ITT population. 
Patients who return randomized product bottles with evidence of intentional tampering or 
unblinding will be excluded from the ITT population and included in the Safety population. 
Safety Population 
All patients who were randomized and received study product will be included in the Safety 
population. 
8. STATISTICAL ANALYSIS METHODS 
If not otherwise specified, statistical significance is defined asp< 0.05 and is two-tailed. Data 
will be summarized with respect to demographic and baseline characteristics and safety 
variables. 
For categorical variables, the number and percent of each category within a parameter will be 
calculated for non-missing data. For continuous variables, statistics will include n, mean, 
standard deviation, median, minimum and maximum values. 
All statistical analyses will be conducted using SAS®, Version 9.4 or higher. Datasets will be 
prepared using headings from Clinical Data Interchange Consortium (CDISC) Study Data 
Tabulation Model (SDTM) implementation for human clinical trials and ADaM (Analysis 
Dataset Model). 
8.1 Baseline Characteristics 
8.1.1 Patient Disposition 
The patient disposition information will be summarized by treatment group. The number of 
patients randomized, treated with study medication will be tabulated by treatment group. In 
addition, completion status and primary reason for withdrawal will be summarized by treatment 
group. 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 14 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
8.1.2 Demographic and Other Baseline Characteristics 
Baseline comparability of all treatment groups will be evaluated separately in the ITT and Safety 
populations. 
The following baseline demographics (determined from their initial study visit) will be 
evaluated: 
• Age (years) 
• Gender (male/female) 
• Ethnicity (Hispanic/non-Hispanic) 
• Race (White, Black/African American, Native Hawaiian or Other Pacific Islander, 
Asian, American Indian or Alaska Native, Other) 
Summary tables by treatment group will be presented. Continuous variables will be summarized 
using descriptive statistics (n, mean, standard deviation, median, minimum, maximum). 
Categorical variables will be summarized using frequencies and percentage. 
Baseline comparability of the treatments will be presented using Chi-square test for the 
categorical variables, and Analysis of Variance for the continuous variables. 
All data will be listed by treatment group and patient. 
8.1.3 Medical History 
At Visit l, patients will be questioned about medical history, including acute and chronic 
medical history and medical history relevant to their onychomycosis. 
Medical history data will be listed by treatment group and patient. 
8.1.4 Concomitant Medications 
At Visit 1, patients will be questioned about current and concomitant medication use over the 
previous 6 months. At all other clinic visits, patients will be questioned about ongoing or new 
concomitant medication use. 
All prior and concomitant medications taken since screening until the end of the study will be 
listed by treatment group and patient. 
8.2 Efficacy Analyses 
8.2.1 Efficacy Analyses on Primary and Secondary Endpoints 
The ITT population will be used to evaluate the efficacy ofNovexatin® 10% topical solution for 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 15 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
the 8-week treatment regimens in Groups A, B and C. 
Descriptive statistics will be summarized for the primary and secondary endpoints (including 
planimetry data) by study group. As this is a multi-centered study, results may also be presented 
by study site. 
In order to preserve an overall type-! error (alpha) of 5% for evaluation of complete and almost 
complete therapeutic cure, complete and satisfactory clinical cure and mycologic cure, a 
hierarchical evaluation scheme will be employed for the primary and secondary endpoints. The 
four comparisons of interest for the primary endpoint and the secondary endpoints -1 and -2 are: 
1. Group B versus Group C-at the test-of-cure visit at Day 365 
2. Group A versus Group C-at the test-of-cure visit at Day 365 
3. Group B versus Group A-at the test-of-cure visit at Day 365 
4. (Group A+ Group B) versus Group C-at the test-of-cure visit at day 141 
The five comparisons of interest for the secondary endpoints -3 and -4 are: 
1. Group B versus Group C -at the test-of-cure visit at Day 365 
2. Group A versus Group C-at the test-of-cure visit at Day 365 
3. Group B versus Group A-at the test-of-cure visit at Day 365 
4. (Group A+ Group B) versus Group C-at the test-of-cure visit at Day 281 
5. (Group A+ Group B) versus Group C-at the test-of-cure visit at Day 141 
Statistical testing will begin with comparison 1. If statistical significance is attained with 
comparison 1 (p < 0.05), then a claim of superiority for comparison 1 can be made and the next 
comparison in the hierarchical evaluation scheme can be tested for statistical significance. If 
statistical significance is not attained for comparison 1 (p ~ 0.05), then testing of all subsequent 
comparisons is stopped. The hierarchical, conditional-stepwise evaluation scheme allows for 
each comparison to be evaluated at the 5% level, while preserving an overall type I error rate of 
no more than 5%. For the proportion of patients in each treatment group with a complete and 
almost complete therapeutic cure, complete and satisfactory clinical cure and mycological cure 
of onychomycosis of the target toenail, the statistical analysis for superiority will be conducted 
using a two-sided Cochran-Mantel-Hacnszel (CMH) exact test, stratified by clinical site, at the 
5% significance level. The primary and secondary analyses will be performed using an observed 
case (OC) analysis in the ITT population. Patients discontinued because of lack of treatment 
effect will be included in the primary analysis as treatment failures. 
The following two sensitivity analyses will also be performed on the primary efficacy endpoint 
in the hierarchical, conditional-stepwise evaluation scheme: 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 16 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404171442603 
1. Analysis will be performed also including patients without an assessment at Day 
365 ± 14. Patients with missing data at Day 365 ± 14 will be considered 
therapeutic failures. 
2. Analysis will be performed also including patients without an assessment at Day 
365 ± 14. Patients in Group C with missing data at Day 365 ± 14 will be treated 
as therapeutic successes and patients from the Groups A and B with missing data 
at Day 365 ± 14 will be treated as therapeutic failures. 
Similar sensitivity analyses will be conducted including patients without an assessment at Day 
141 ± 7 for the 4th comparison in the hierarchical, conditional-stepwise evaluation scheme. 
8.2.2 Treatment-by-Site Interaction and Pooling of Clinical Sites 
As this is a multiple-site study, the interaction of treatment-by-site may be evaluated for 
superiority testing by the Cochrim-Mantei-Haenszel test (stratified by site) using Breslow-Day 
test for the primary efficacy endpoint at the 5% significance level (p < 0.05, 2-sided) in the ITI 
population. A site(s) with a low enrollment rate(s) may be pooled with its geographically closest 
site, so as to avoid bias in the stratification of the sites in the CMH test and in the estimation of a 
treatment-by-site interaction effect. The pooling will be done for low enrolling sites that account 
for less than 4-7% of the total number of patients in the ITT population at the site with the 
highest enrolling rate. If no treatment-by-site interaction is identified with the primary endpoints 
then no adjustment will be made to any efficacy analysis. 
8.2.3 Additional Analyses 
In addition to the efficacy statistical analyses specified in the protocol, the analyses described in 
Section 8.2.1 above, including sensitivity analyses, will also be performed using the following 
endpoints: 
1. Primary endpoint (complete therapeutic cure) with Canfield's evaluation for % toenail 
involvement. 
2. Secondary endpoint #1 (complete or almost complete therapeutic cure) with Canfield's 
evaluation for% toenail involvement for complete cure in addition to the current 
evaluation for almost complete cure by Canfield's evaluation. 
3. Secondary endpoint #3 (complete clinical cure) with Canfield's evaluation for% toenail 
involvement for complete cure. 
Patients will only be included in analyses 1, 2 and 3 above if they meet inclusion criterion #6 
(Mild to moderate severity at Visit 1 as defined by Investigator's estimation of approximately 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 17 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
I 0% to 35% toenail involvement) on the basis of Canfield's evaluation to define mild to 
moderate severity instead ofby Investigator's estimation. 
8.3 Safety Analysis 
All study patients who are randomized to the active treatment period of the study, and received 
study product will be included in the comparative safety analysis. The safety profile of each 
treatment group will be evaluated by comparing adverse events, application site reactions, vital 
signs and changes in clinical laboratory results obtained throughout the study. Data will also be 
collected during the study to compare the results of the KOH stains to the mycological culture 
results observed during the study. 
8.3.1 Adverse Events 
All the adverse events (AEs) reported throughout the study will be coded and classified 
according to the MedDRA (Medical Dictionary for Regulatory Activities) coding dictionary 
(Version 19.0 or higher). Each adverse event is to be evaluated for date of start and end, 
seriousness, severity, causal relationship with the study drugs, action taken and outcome. 
All AEs will be listed by treatment group and patient. 
A summary table of the number and percent of patients with AEs by system organ class, 
preferred term, and treatment will be presented. Each patient will be counted only once within 
each preferred term. Other summaries may be added based on the obtained data. 
A frequency summary table of the number of AEs by system organ class, preferred term, 
severity, and treatment will be presented. Severity will be classified as "Mild", "Moderate", or 
"Severe". 
Similarly, a frequency summary table of the number of AEs by system organ class, preferred 
term, and relationship to a study drug, and treatment will be presented. Relationship to a study 
drug will be classified as "Not Related" or "Related" where "Related includes "Possible", 
"Probable", or "Definite". 
Should sufficient data exist, adverse event frequencies will be compared between treatments 
using Fisher's exact test. If the global Fisher's exact test is statistically significant among the 
three treatment groups at the 5% alpha level (i.e., p < 0.05), then Fisher's exact test using only 
the Group A and Group B may be performed to identifY any potential statistically significant 
differences that are clinically relevant between the two active treatment groups over the period 
from Day 1 to Day 141 ± 7 days (i.e., following completion of the first 8 weeks of treatment 
when both groups have the same test treatment regimen) and over the study duration from Day I 
to Day 365 ± 14 days. 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 18 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
8.3.2 Vital Signs 
The patient's vital signs will be recorded (heart rate, blood pressure, temperature and respiration 
rate) at Visits 1, 3, 5, 6 and 7. 
Descriptive summaries (number of observations, mean, standard deviation, minimum, median 
and maximum) will be provided by treatment group and visit. 
8.3.3 Clinical Laboratory Results 
Clinical laboratory results (hematology, chemistry and urinalysis) will be collected at Visits I, 3 
and 7. 
Descriptive summaries (number of observations, mean, standard deviation, minimum, median 
and maximum) will be provided by treatment group and visit. 
All data will be listed by treatment group and visit. 
8.3.4 Application Site Reactions 
At Visits 3, 4, 5, 6 and 7, the Investigator will examine the treatment area and complete the signs 
and symptoms of irritation assessment. 
A frequency summary table comparing the application site reactions for each treatment group 
will be presented by visit. 
All data will be listed by treatment group and patient. 
8.3.5 Evaluation of Toenail Condition/ Appearance: 
The toenail, one of the two great toenails, that the investigator considers to be the most 
appropriate as the target toenail will be identified and designated as the "target toenail" at Visit 2 
and used for evaluations. 
The overall appearance of the target toenail over time will be monitored during the study: 
1. Self-assessed by patients. The results of the self-assessment will be recorded by the 
patient before beginning therapy at Visit 2 and at all subsequent visits. Patients will 
use a 5-point scale (see Appendix A) for target toenail appearance. 
2. Assessed by Investigator: Investigators will rate the status of the target toenail before 
beginning therapy at Visit 2 and at all subsequent visits. Nail condition/appearance by 
investigator will be evaluated after nail trimming to the distal groove and before 
further trimming, if required, for the mycological evaluation. Investigators will use a 
5-point scale (see Appendix A) target toenail appearance. 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 19of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
A frequency summary table for each treatment group will be presented by visit. 
All data will be listed by treatment group, patient, and evaluation day. 
8.4 Multiple Comparisons 
No multiple comparison adjustment will be made in this study other than the pre-defined 
hierarchical testing for the primary and secondary endpoints. 
8.5 Methods for Handling Missing Data 
For demographic and baseline characteristics, each variable will be analyzed using all available 
data. Patients with missing data will be excluded only fi·om analyses for which data are not 
available. 
The following rules and conventions will be used for patients who terminate from the study early 
or are dropped from the study because of protocol deviations. 
Any patient who either requests to be dropped from the study because oflack of therapeutic 
efficacy or is dropped by the Investigator for Jack of therapeutic efficacy will automatically be 
considered a "clinical failure" regardless of their target toenail assessment score at the 
termination visit. 
Any patient who uses any protocol restricted medication specifically for the treatment of their 
infection will be discontinued from further participation in the study and automatically be 
considered a "clinical failure" regardless of their target toenail assessment score at the last visit. 
Any patient who uses any protocol restricted medication NOT specit1cally for the treatment of 
their onychomycosis will be discontinued from further participation in the study. The patient will 
be considered a "clinical cure" or "clinical failure" based on the target toenail assessments at the 
termination visit. 
Any patient who is dropped for any reason other than those covered above will be included in the 
ITT, provided they had a positive baseline culture and applied at least one dose of the study 
product. Examples would include: failure to use the study products as required by the protocol, 
patient withdraws consent for continued participation, patient fails to make study visits on a 
timely basis. 
8.6 Interim Analyses 
There is no interim analysis planned in this study. 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 20 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
8.7 Changes to the Protocol Defined Statistical Analysis Plan 
The protocol states that the statistical analysis for superiority will be conducted using two-sided 
Z-Tests and a pooled response rate for the standard error of the difference in proportions for each 
comparison of interest. The CMH exact test stratified by clinical site is preferred for a multi-site 
study for which the randomization is intended to be balanced among treatments within each site 
(i.e., stratified by site), because it accounts for the variability in clinical site whereas the Z-test 
does not account for site variability in the model. During the analysis, the statistical analysis for 
superiority will be conducted using a two-sided Cochran-Mantel-Haenszel (CMH) exact test, 
stratified by clinical site, at the 5% significance level. 
The wording in section 8.5 "Methods for Handling Missing Data" was updated to coincide with 
the ITT definition. The ITT states that patients will be included in the ITT as long as they have 
received one dose of assigned study product and had a positive mycological culture at Visit 1. 
Additional analyses that were not delineated in the protocol were included in section 8.2.3 of the 
SAP. 
9. TABLE, LISTING AND FIGURE SHELLS 
The following shells provide a framework for the display of data from this study. These shells 
may not be reflective of every aspect of this study but are intended to show the general layout of 
the Tables, Listings and Figures that will be included in the final clinical study report. Tables, 
Listings and Figures are numbered following the ICH structure. Table headers, variables names 
and footnotes will be modified as needed following data analyses. All descriptive and inferential 
statistical analyses will be performed using SAS® statistical software Version 9.4 or higher, 
unless otherwise noted. 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 21 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
3/2112018 Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
TABLE, LISTING AND FIGURE SHELLS 
• Taro Pharmaceuticals U.S.A., Inc. • Page 22 of71 
Taro Pharmaceuticals U.S.A., Iuc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Tables for Report Body 
3/21/2018 Population 
Safety 
ITT Total 
XXX 
XXX Table I Number of Patients 
Treatment Treatment Treatment 
Group A Group B Group C 
XXX 
XXX XXX 
XXX XXX 
XXX 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo treatment for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Appendix 16.2.3 
• Taro Pharmaceuticals U.S.A., Inc. • Page 23 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Patients 
Screened 
Randomized 
Completed Study 
Terminated Early 
Adverse event 
Lack of efficacy 
Lost to follow-up 
etc. 
Other Table II Summary of Patient Disposition 
Treatment Treatment 
Group A Group B 
XXX XXX 
XXX XXX 
XXX XXX 
XXX XXX 
XXX XXX 
XXX XXX 
XXX XXX Treatment 
Group C 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
Treatment Group A: Novexatin® IO% Topical Solution for Days I-56 and Placebo treatment for Days 28I-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I -56 and Days 28 I -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Appendix 16.2.1 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Total 
XXX 
XXX 
XXX XXX 
XXX 
XXX 
XXX 
XXX 
Page 24 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404171442603 
Table III Summary of Protocol Deviations 
Treatment Treatment Treatment 
Group A Group B Group C 
N=xxx N=xxx N=xxx 
Total Patients with Protocol Deviations XXX XXX XXX 
Total Deviations XXX XXX XXX 
Lost to Follow-up XXX XXX XXX 
Missed Visit XXX XXX XXX 
Non-compliance with study drug XXX XXX XXX 
etc XXX XXX XXX 
Other XXX XXX XXX 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo treatment for Days 281 -336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281 -336 
Source: Appendix 16.2.2 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Total 
N=xxx 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
Page 25 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Table IV Summary of Patients Excluded from Efficacy Analysis 
Treatment Treatment Treatment 
Group A Group B Group C 
N=xxx N=xxx N=xxx 
Safety Population XXX XXX XXX 
Excluded from Safety population XXX XXX XXX 
ITT Population XXX XXX XXX 
Excluded from ITT population XXX XXX XXX 
Inclusion/Exclusion criteria not met XXX XXX XXX 
etc. XXX XXX XXX 
Treatment Group A: Novexatin® I 0% Topical Solution for Days I-56 and Placebo treatment for Days 28 I -336 
Treatment Group B: Novexatin® I 0% Topical Solution for Days I -56 and Days 28 I -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1 -56 and Days 28I -336 
Source: Appendix 16.2.3 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Total 
N=xxx 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
Page 26 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Table V Summary of Superiority Analysis Results of Primary Efficacy Endpoint 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to-Treat Population- Observed Case Analysis) 
Number of Patients Proportion of Patients 
Test of Number of Patients with Complete with Complete 
Cure Treatment Comparison (N) Therapeutic Cure (n) Therapeutic Cure(%) Difference 
Visit Group 1 versus Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 Group 2 (%) 
Day 365 Group B versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Group A versus Group C XXX XXX XXX XXX xx.x xx.x XX .X 
Group B versus Group A XXX XXX XXX XXX xx.x xx.x xx.x 
Day 141 Group A+B versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using CMH exact test) in the ITT population using observed case. 
# P-value will not be presented if the preceding one is >=0.05. 
Treatment Group A: Novexatin® 10% Topical Solution for Days l-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 281-336 
Source: Listing Ll6.2.6.5.1, adeff 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • P-value # 
0.0056 
0.0842 
NA 
NA 
Page 27 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Table VI Sensitivity Analysis #1: Superiority Analysis Results of Primary Efficacy Endpoint 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population) 
Number of Patients Proportion of Patients 
Test of Number of Patients with Complete with Complete 
Cure Treatment Comparison (N) Therapeutic Cure (n) Therapeutic Cure(%) Difference 
Visit Group 1 versus Group 2 Group 1 Group 2 Group 1 Group 2 Group 1 
Day 365* Group B versus Group C XXX XXX XXX XXX XX. X 
Group A versus Group C XXX XXX XXX XXX xx.x 
Group B versus Group A XXX XXX XXX XXX xx.x 
Day 141 ** Group A+B versus Group C XXX XXX XXX XXX XX. X 
Superiority testing was conducted at the 5% significance level (p < 0.05; using CMH exact test) in the ITT population. 
# P-value will not be presented if the preceding one is >=0.05. 
*Patients with missing data at Day 365 ± 14 are considered therapeutic failures. 
**Patients with missing data at Day 141 ± 7 are considered therapeutic failures. Group 2 
xx.x 
xx.x 
XX. X 
XX. X 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® I 0% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Listing L16.2.6.5.3, adeff 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • (%) 
XX. X 
xx.x 
xx.x 
xx.x P-value # 
0.0056 
0.0842 
NA 
NA 
Page 28 of? I 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Table VII Sensitivity Analysis #2: Superiority Analysis Results of Primary Efficacy Endpoint 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population) 
Number of Patients Proportion of Patients 
Test of Number of Patients with Complete with Complete 
Cure Treatment Comparison (N) Therapeutic Cure (n) Therapeutic Cure (%) Difference 
Visit Group 1 versus Group 2 Group 1 Group 2 Group 1 Group2 Group 1 Group 2 (%) 
Day 365* Group B versus Group C XXX XXX XXX XXX XX. X xx.x xx.x 
Group A versus Group C XXX XXX XXX XXX XX. X xx.x xx.x 
Group B versus Group A XXX XXX XXX XXX XX. X xx.x XX. X 
Day 141** Group A +B versus Group C XXX XXX XXX XXX xx.x xx.x XX. X 
Superiority testing was conducted at the 5% significance level (p < 0.05; using C:MH exact test) in the ITT population. 
# P-value will not be presented if the preceding one is >=0.05. 
*Patients in Group C with missing data at Day 365 ± 14 are considered therapeutic successes and patients in Groups A and B with missing data 
at Day 365 ± 14 are considered therapeutic failures. 
**Patients in Group C with missing data at Day 141 ± 7 are considered therapeutic successes and patients in Groups A and B with missing data 
at Day 141 ± 7 are considered therapeutic failures. 
Treatment Group A: Novexatin® 10% Topical Solution for Days l-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Listing Ll6.2.6.5.3, adeff P-value # 
0.0056 
0.0842 
NA 
NA 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 29 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Table VIII Summary of Adverse Events (Safety Population) 
Description 
Patients with AEs 
Patients with at least one AE 
Discontinued study drug due to 
aboveAE 
AEs reported 
Mild 
Moderate 
Severe 
Not Related 
Related 
Death 
Serious AE 
Related includes "Possible", "Probable", or "Definite" related. Treatment 
Group A 
N=xxx 
xx(xx.x%) 
xx (xx.x%) 
XX 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) Treatment Treatment 
Group B Group C 
N=xxx N=xxx 
xx (xx.x%) xx (xx.x%) 
xx (xx.x%) xx (xx.x%) 
XX XX 
xx (xx.x%) xx (xx.x%) 
xx (xx.x%) xx (xx.x%) 
xx(xx.x%) xx (xx.x%) 
xx(xx.x%) xx (xx.x%) 
xx (xx.x%) xx (xx.x%) 
xx (xx.x%) xx (xx.x%) 
xx (xx.x%) xx (xx.x%) 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo 0fehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281-336 
Treatment Group C: Placebo 0fehicle) Topical Solution for Days I -56 and Days 281-336 
Source: Listing 16.2.7.1 
3/2l/2018 • Taro Pharmaceuticals U.S.A., Inc. • Total 
N=xxx 
xx(xx.x%) 
xx (xx.x%) 
XX 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx (xx.x%) 
xx(xx.x%) 
xx(xx.x%) 
xx (xx.x%) 
Page 30 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Tables for section 14 Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.1.1 Summary of Patients Included in Analysis Population by Study Center 
Safety ITT 
Site PI Total Group A Group B Group C Total Group A Group B Group C Total No. Name Randomized 
XX xxxx XXX XXX XXX XXX XXX XXX XXX XXX XXX 
XX xxxx XXX XXX XXX XXX XXX XXX XXX XXX XXX 
Treatment Group A: Novexatin® 10% Topical Solution for Days I-56 and Placebo (Vehicle) Topical Solution for Days 28I-336 
Treatment Group B: Novexatin® I 0% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281 -336 
Source: Listing LI6.2.4.1, ads! 
Created on: ddmmmyy hh:mm 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 31 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Age (years) 
Race 
Ethnicity 
Gender T14.1.2.1 Summary of Demographic Data 
(Safety Population) 
Treatment Treatment Treatment 
Group A Group B Group C 
N=xxx N=xxx N=xxx 
n XX XX XX 
Mean±SD xx.x±x.x xx.x±x.x xx.x±x.x 
Median XX. X XX. X xx.x 
Range xx-xx XX-XX xx-xx 
American Indian or Alaska Native xx (xx.x%) xx (xx.x%) xx(xx.x%) 
Asian xx (xx.x%) xx (xx.x%) xx(xx.x%) 
Black/African American xx (xx.x'%) xx(xx.x%) xx(xx.x%) 
Native Hawaiian or other Pacific xx (xx.x%) xx (xx.x%) xx(xx.x%) Islander 
White xx (xx.x"/o) xx (xx.x%) XX (xx.x%) 
Other XX (xx.x"/o) XX (xx.x"/o) xx (xx.x%) 
Hispanic or Latino xx (xx.x"/o) xx(xx.x%) xx(xx.x%) 
Not Hispanic or Latino xx (xx.x%) xx(xx.x%) xx(xx.x%) 
Female xx (xx.x%) xx (xx.x%) xx(xx.x%) 
Male xx (xx.x%) xx (xx.x%) xx (xx.x%) 
N= number of patients in the treatment; n= number of patients with data available; % is based on N Total 
N=xxx P-value 
XX x.xxxx 
xx.x±x.x 
xx.x 
XX·XX 
xx (xx.x%) x.xxxx 
xx (xx.x%) 
xx (xx.x%) 
xx(xx.x%) 
xx (xx.x%) 
xx(xx.x%) 
xx (xx.x%) x.xxxx 
xx(xx.x%) 
xx(xx.x%) x.xxxx 
xx (xx.x%) 
Treatment Group A: Novexatin® 10% Topical Solution for Days I-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 281-336 
Source: Listing Ll6.2.4.1 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 32 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Similar tables will be created for Tl4.1.2.2 Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.1.2.2 Summary of Demographic Data (Intent-to-Treat Population) 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 33 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.2.1 Summary of Superiority Analysis Results of Primary Efficacy Endpoint Using Canfield Evaluation 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to-Treat Population- Observed Case Analysis) 
Number of Patients Proportion of Patients 
Number of Patients with Complete with Complete Test of 
Cure 
Visit Treatment Comparison 
Group l versus Group 2 (N) Therapeutic Cure (n) Therapeutic Cure (%) Difference 
Group l Group 2 Group I Group 2 Group 1 Group 2 (%) 
Day 365 Group B versus Group C xxx xxx XXX XXX XX. X XX. X xx.x 
Group A versus Group C xxx xxx XXX XXX xx.x XX. X xx.x 
Group B versus Group A xxx xxx XXX XXX xx.x XX. X XX. X 
Day 141 Group A+B versus Group C xxx xxx XXX XXX xx.x xx.x xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using CMH exact test) in the ITT population using observed case. 
# P-value will not be presented if the preceding one is >=0.05. 
Treatment Group A: Novexatin® IO% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 28I-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 P-value # 
0.0056 
0.0842 
NA 
NA 
Source: Listing L 16.2.6.5 .3, adeff 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 34 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
T14.2.2 Sensitivity Analysis #1: Superiority Analysis Results of Primary Efficacy Endpoint Using Canfield Evaluation 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population) 
Number of Patients Proportion of Patients 
Test of Number of Patients with Complete with Complete 
Cure Treatment Comparison (N) Therapeutic Cure (n) Therapeutic Cure (%) Difference 
Visit Group 1 versus Group 2 Group 1 Group 2 Group 1 Group2 Group 1 
Day 365* Group B versus Group C XXX XXX XXX XXX xx.x 
Group A versus Group C XXX XXX XXX XXX xx.x 
Group B versus Group A XXX XXX XXX XXX xx.x 
Day 141 ** Group A +B versus Group C XXX XXX XXX XXX xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using C:tyiH exact test) in the ITT population. 
# P-value will not be presented if the preceding one is >=0.05. 
*Patients with missing data at Day 365 ± 14 are considered therapeutic failures. 
**Patients with missing data at Day 141 ± 7 are considered therapeutic failures. Group2 
xx.x 
xx.x 
XX .X 
xx.x 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 281-336 
Source: Listing L16.2.6.5.3, adeff 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • (%) P-value# 
xx.x 0.0056 
xx.x 0.0842 
xx.x NA 
xx.x NA 
Page I ofN 
Page 35 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.2.3 Sensitivity Analysis #2: Superiority Analysis Results of Primary Efficacy Endpoint Using Canfield Evaluation 
(Proportion of Patients with Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population) 
Number of Patients Proportion of Patients 
Test of Number of Patients with Complete with Complete 
Cure Treatment Comparison (N) Therapeutic Cure (n) Therapeutic Cure(%) Difference 
Visit Group I versus Group 2 Group 1 Group 2 Group 1 Group2 Group 1 Group 2 (%) 
Day 365* Group B versus Group C XXX XXX XXX XXX xx.x XX. X xx.x 
Group A versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Group B versus Group A XXX XXX XXX XXX xx.x xx.x XX. X 
Day 141** Group A +B versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using Cl"v1H exact test) in the ITT population. 
# P-value will not be presented if the preceding one is >=0.05. 
*Patients in Group C with missing data at Day 365::: 14 are considered therapeutic successes and patients in Groups A and B with missing data 
at Day 365 ± 14 are considered therapeutic failures. 
**Patients in Group C with missing data at Day 141 ± 7 are considered therapeutic successes and patients in Groups A and B with missing data 
at Day 141 ± 7 are considered therapeutic failures. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 P-value# 
0.0056 
0.0842 
NA 
NA 
Source: Listing Ll6.2.6.5.3, adeff 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 36 of71 
Taro Pharmaceuticals U.S.A., Iuc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.2.4.1 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-! 
(Proportion of Patients with Complete or Almost Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population- Observed Case Analysis) 
Number of Patients Proportion of Patients 
Test of Number of Patients with Complete or with Complete or 
Cure Treatment Comparison (N) Almost Complete Almost Complete 
Visit Group I versus Group 2 Therapeutic Cure (n) Therapeutic Cure(%) Difference 
Group I Group 2 Group 1 Group 2 Group I Group 2 (%) 
Day 365 Group B versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Group A versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Group B versus Group A XXX XXX XXX XXX xx.x XX. X xx.x 
Day 141 Group A+B versus Group C XXX XXX XXX XXX xx.x xx.x xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using Cl\1H exact test) in the ITT population using observed case. 
# P-value will not be presented if the preceding one is >=0.05. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 P-value # 
0.0056 
0.0842 
NA 
NA 
Source: Listing L16.2.6.5 .1, adeff 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 37 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.2.4.2 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint- I Using Canfield Evaluation 
(Proportion of Patients with Complete or Almost Complete Therapeutic Cure at the Test-of-Cure Visits) 
(Intent-to-Treat Population- Observed Case Analysis) 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 38 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Test of T14.2.5 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-2 
(Proportion of Patients with Mycologic Cure at the Test-of-Cure Visits) 
(Intent-to-Treat Population- Observed Case Analysis) 
Number of Proportion of 
Number of Patients Patients with Patients with 
Cure Treatment Comparison (N) Mycologic Cure (n) Mycologic Cure(%) Difference 
Visit Group l versus Group 2 Group 1 Group 2 Group 1 Group 2 Group l Group 2 (%) 
Day 365 Group B versus Group C XXX XXX XXX XXX xx.x XX.X XX. X 
Group A versus Group C XXX XXX XXX XXX xx.x XX. X xx.x 
Group B versus Group A XXX XXX XXX XXX xx.x xx.x xx.x 
Day 141 Group A +B versus Group C XXX XXX XXX XXX xx.x XX. X xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using CMH exact test) in the ITT population using observed case. 
# P-value will not be presented if the preceding one is >=0.05. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 P-value # 
0.0056 
0.0842 
NA 
NA 
Source: Listing LI6.2.6.5.l, adeff 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 39 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Test of T14.2.6.1 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-3 
(Proportion of Patients with Complete Clinical Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population- Observed Case Analysis) 
Number of Patients Proportion of Patients with 
Number of Patients with Complete Complete 
Cure Treatment Comparison (N) Clinical Cure (n) Clinical Cure(%) Difference 
Visit Group I versus Group 2 Group l Group 2 Group l Group2 Group l Group 2 (%) 
Day 365 Group B versus Group C XXX XXX XXX XXX XX. X xx.x xx.x 
Group A versus Group C XXX XXX XXX XXX xx.x XX. X XX. X 
Group B versus Group A XXX XXX XXX XXX XX. X XX. X XX. X 
Day 281 Group A+B versus Group C XXX XXX XXX XXX xx.x xx.x XX. X 
Day 141 Group A+B versus Group C XXX XXX XXX XXX xx.x XX. X XX. X 
Superiority testing was conducted at the 5% significance level (p < 0.05; using CMH exact test) in the ITT population using observed case. 
# P-value will not be presented if the preceding one is >=0.05. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 P-value # 
0.0056 
0.0842 
NA 
NA 
NA 
Source: Listing Ll6.2.6.5.1, adeff 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/2!/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page40 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.2.6.2 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-3 Using Canfield Evaluation 
(Proportion of Patients with Complete Clinical Cure at the Test-of-Cure Visits) 
(Intent-to-Treat Population- Observed Case Analysis) 
3/2ll2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 41 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.2.7 Summary of Superiority Analysis Results of Secondary Efficacy Endpoint-4 
(Proportion of Patients with Satisfactory Clinical Cure at the Test-of-Cure Visits) 
(Intent-to- Treat Population- Observed Case Analysis) 
Number of Patients Proportion of Patients with 
Number of Patients with Satisfactory Satisfactory Test of 
Cure 
Visit Treatment Comparison 
Group 1 versus Group 2 (J'<) Clinical Cure (n) Clinical Cure (%) Difference 
Group l Group 2 Group 1 Group 2 Group 1 Group 2 (%) 
Day 365 Group B versus Group C xxx xxx XXX XXX xx.x xx.x XX. X 
Group A versus Group C xxx xxx XXX XXX XX. X xx.x xx.x 
Group B versus Group A xxx xxx XXX XXX xx.x XX. X XX. X 
Day 281 Group A+B versus Group C xx:x xxx XXX XXX XX. X XX. X XX. X 
Day 141 Group A +B versus Group C xxx xxx XXX XXX xx.x XX. X xx.x 
Superiority testing was conducted at the 5% significance level (p < 0.05; using Cl\.1H exact test) in the ITT population using observed case. 
# P-value will not be presented if the preceding one is >=0.05. 
Treatment Group A: Novexatin® 10% Topical Solution for Days J-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 P-value# 
0.0056 
0.0842 
NA 
NA 
NA 
Source: Listing Ll6.2.6.5.1, adeff 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 42 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
T14.3.1.1 Summary of Frequency of All Adverse Events by Body System: Day 1 to Day 141 ± 7 
(Safety Population) 
Treatment Group A Treatment Group B Treatment Group C 
(N = xxx) (N = xxx) (N = xxx) 
Body System MedDRA Term E Patients E Patients E t Patients Fisher's vents (01) vents co/) ven s (o") 1 n to n to n 10 p-va ue 
Patients with at least one AE Total XX XX (XX.X) XX XX (xx.x) XX XX (xx.X) X.XXXX 
Ear and labyrinth disorders Ear pain XX XX (XX.X) XX XX (xx.X) XX XX (xx.X) X.XXXX 
etc. 
etc. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Listing Ll6.2.7.1 
Created on: ddmmmyy hh:mm Page I ofN 
3/21/2018 T14.3.1.2 Summary of Frequency of All Adverse Events by Body System: Day 1 to Day 365 ± 14 
(Safety Population) 
• Taro Pharmaceuticals U.S.A., Inc. • Page 43 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.3.2 Summary of Frequency of All Adverse Events by Relationship 
(Safety Population) 
Body System MedDRA Term 
Patients with at least one AE Total 
Ear and labyrinth disorders Ear pain 
etc. 
etc. Treatment Group A 
#of Events 
(N=xxx) Treatment Group B Treatment Group C 
#of Events # of Events 
(N = xxx) (N = xxx) 
Related 
n(%) 
xx (xx.x) 
xx (xx.x) Not Not R 1 ted Related Not Related Related R 1 t d 
:(~) n(%) n(%) n(%) :(~~ 
xx (xx.x} xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
N =Total number of events in each treatment group; Percentage is based on total number of events. 
Related includes "Possible", "Probable", or "Definite" related. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Listing Ll6.2. 7.1 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 44 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
T14.3.3 Summary of Frequency of All Adverse Events by Severity 
(Safety Population) 
MedORA Mild Body System Term n(%) 
Patients with at Total xx (xx.x) least one AE 
Ear and labyrinth Ear pain xx (xx.x) disorders 
etc. 
etc. Treatment Group A 
#of Events 
(N=xxx) Treatment Group B 
#of Events 
(N=xxx) Treatment Group C 
#ofEvents 
(N=xxx) 
Moderate Severe Mild Moderate Severe Mild Moderate Severe 
n(%) n(%) _n(')fo}_ __nlli} n(%) _11_~ n(%) n(%) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx(xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
N =Total number of events in each treatment group; Percentage is based on total number of events. 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281 -336 
Source: Listing L16.2.7.1 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 45 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Body System 
Injury, poisoning and 
procedural complications T14.3.4 Summary of Frequency of Serious Adverse Events 
(Safety Population) 
Treatment Treatment 
MedDRA Term Group A Group B 
N=xx N=xx 
#of Events #of Events 
Alcohol poisoning XX Treatment 
Group C 
N=xx 
#of Events 
XX 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281 -336 
Source: Listing L 16.2. 7.1 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 46 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Vital Sign (unit) 
Systolic Blood Pressure (mmHg) 
Diastolic Blood Pressure (mmHg) 
Heart Rate (beats/min) 
Respiration Rate (breaths/min) 
Temperature (F) Visit 
3 
5 
6 
7 T14.3.5 Summary of Vital Signs 
(Safety Population) 
Treatment 
Statistic Group A 
N=xx 
n XX 
Mean±SD xxx.x±xx.x 
Median XXX. X 
Range xxx-xxx Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Treatment 
Group B 
N=xx 
XX 
xxx.x± xx.x 
xxx.x 
XXX-XXX Treatment 
Group C 
N=xx 
XX 
xxx.x±xx.x 
XXX. X 
XXX-XXX 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Listing L16.2.8.4 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Pagel ofN 
Page 47 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Lab Test (unit) 
Hemoglobin (giL) 
Hematocrit (LIL) 
etc T14.3.6 Summary of Clinical Laboratory Testing (Hematology) 
(Safety Population) 
Treatment Treatment 
Visit Statistic Group A Group B 
N=xx N=xx 
1 n XX XX 
Mean± SD xxx.x±xx.x xxx.x±xx.x 
Median xxx.x xxx.x 
Range XXX-XXX XXX-XXX 
3 
7 Treatment 
Group C 
N=xx 
XX 
xxx.x±xx.x 
xxx.x 
XXX-XXX 
Treatment Group A: Novexatin"' 10% Topical Solution for Days I -56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1 -56 and Days 281 -336 
Source: Listing L16.2.8.1 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 T14.3.7 Summary of Clinical Laboratory Testing (Chemistry) 
(Safety Population) 
T14.3.8 Summary of Clinical Laboratory Testing (Urinalysis) 
(Safety Population) 
• Taro Pharmaceuticals U.S.A., Inc. • Page 48 of7l 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Signs and Symptoms 
Erythema (redness) 
Scaling/Dryness 
Stinging/Burning 
Erosion 
Edema (swelling) 
Pain 
Itching T14.3.9 Summary of Frequency of Application Site Reactions 
(Safety Population) 
Visit 
3 
4 
5 
6 
7 Scale 
Absent 
Mild 
Moderate 
Severe Treatment 
Group A 
N=xx 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) Treatment 
Group B 
N=xx 
xxx(xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) Treatment 
Group C 
N=xx 
xxx (xx.x"/o) 
xxx (xx.x%) 
xxx (xx.x%) 
xxx (xx.x%) 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Source: Listing Ll6.2.7.2 
Created on: ddmmmyy hh:mm 
3/2!/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 49 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404171442603 
Visit 
Visit2 
Visit3 
Visit 4 
Visit 5 
Visit 6 
Visit 7 T14.3.10 Summary of Frequency of Evaluation of Toenail Condition/Appearance 
(Safety Population) 
Treatment Treatment Treatment 
Group A Group B Group C 
Scale N=xx N=xx N=xx 
Self-assessed by Patients Very Poor xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
Poor xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
Normal xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
Good xxx (xx.x%) xxx(xx.x%) xxx (xx.x%) 
Very Good xxx (xx.x%) xxx(xx.x%) xxx (xx.x%) 
Assessed by Investigator Very Poor xxx (xx.x%) XXX (xx.x%) xxx (xx.x%) 
Poor xxx (xx.x%) xxx (xx.x%) xxx (xx.x%) 
Normal xxx (xx.x%) xxx (xx.x%) xxx(xx.x%) 
Good xxx (xx.x%) xxx (xx.x"/o) xxx (xx.x%) 
Very Good xxx (xx.x%) xxx (xx.x"/o) xxx (xx.x%) 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1 -56 and Days 281 -336 
Source: Listing Ll6.2.6.4 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 50 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Treatment 
Treatment Group A 
Treatment Group B 
Treatment Group C L16.2.1 Listing of Discontinued Patients 
Patient 
Randomization 
Number 
xx-xxxx 
xx-xxxx Discontinuation 
Reason 
Withdrawal by Patient 
Lost to Follow-up Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Population 
Per-Protocol 
Safety 
Treatment Group A: Novexatin® IO% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 28I -336 
Treatment Group B: Novexatin® IO% Topical Solution for Days I -56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 28I-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 51 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C L16.2.2 Listing of Protocol Deviations 
Patient 
Randomization 
Number Event Description Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Population 
xx-xxxx Outside Visit Window (Visit 3) Safety 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mrn Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 52 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C L16.2.3 Listing of Patients Excluded from the Analysis Population 
Patient 
Randomization 
Number 
xx-xxxx Included in Reason. IfNot Included in Reason. IfNot 
Safety Included in Safety ITT Included in ITT 
Population? Population Population? Population 
Yes No xxxxxxxxxxx 
Treatment Group A: Novexatin ® 10% Topical Solution for Days 1 -56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® 10%-Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 53 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Treatment 
Group Patient 
Randomization 
Number 
Treatment Group A xx-xxxx 
Treatment Group B 
Treatment Group C L16.2.4.1 Listing of Demographic Data 
Age Gender Ethnicity 
30 Female Not Hispanic or Latino Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Race 
Black or African American 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1 -56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3121/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 54 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xx-xxxx Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
L16.2.4.2 Listing of Medical History 
Diagnosis or System Start Date Surgical Procedure End Date Ongoing 
Gynecologic Menopause --/--12012 yyyy-mm-dd 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 55 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xx-xxxx Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404171442603 
L16.2.4.3 Listing of Concomitant Medication 
Treatment Start/End 
Area Medication Dosage Frequency* Route Date Indication 
No Advil 2TAB QD Oral --/--/20171 Cold 
08/12/2017 
Treatment Group A: Novexatin® 10% Topical Solution for Days I-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® I 0% Topical Solution for Days 1-56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281 -336 
*PRN-As needed; QD -Daily (once per day); Q4H-Every 4 hours; Q8H-Every 8 hours; Ql2H-Every 12 hours; BID-Twice per day; TID-3 
times per day; QID -4 times per day; QOD -Every other day; QS -Every week; QM -Every month; Q3M-Every 3 months 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 56 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmacentical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
L16.2.5 Listing of Diary Entries and Study Compliance 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xxxx Date of Date of Period First Dose Last Dose 
Period 1 yyyy-mm-dd yyyy-mm-dd 
Period 2 yyyy-mm-dd yyyy-mm-dd Total Did the patient have Did the patient miss 
the scheduled Doses between 75%-125% applications for 4 or Applied dosing compliance? more consecutive days? 
XX No No 
XX No No 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days l-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 57 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
L16.2.6.1 Listing of Investigator Clinical Assessment 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xx-xxxx Visit 
1 
3 
4 
5 
6 
7 Exam Result 
Area 
Foot (Left) Abnormal 
Foot (Right) Normal Number of 
Toenails 
Infected 
2 Nail 
Appearance 
xxxxxxxxx Target Toenail 
Left big toe 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 58 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
L16.2.6.2.1 Listing of Investigator Visual Assessment (Percent Nail Involvement of the Target Toenail) 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xx-xxxx Visit! Visit2 
XXX XXX Visit3 Visit4 VisitS Visit6 Visit7 
XXX XXX XXX XXX XXX 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
L16.2.6.2.2 Listing of Canfield Assessment (Percent Nail Involvement of the Target Toenail) 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 59 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404/71442603 
Treatment 
Group Patient 
Randomization 
Number L16.2.6.3 Listing ofKOH Wet Mount & Mycological Culture 
Was the KOH Wet Mount KOH Wet Was the fungal culture 
Visit sample taken from the Mount Result sample taken from the 
designated Target Toenail? designated Target Toenail? Fungal 
Culture 
Result Reason 
Not Done 
Treatment Group A xx-xxxx 1 
4 
5 
7 Yes Positive Yes Positive 
Treatment Group B 
Treatment Group C 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 1 ofN 
Page 60 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404171442603 
L16.2.6.4 Listing oflnvestigator & Patient Evaluation Of Toenail Appearance & Condition 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xxxx Visit 
2 
3 
4 
5 
6 
7 Investigator 
Evaluation 
I Very Poor 
2 Poor Patient 
Evaluation 
2 Poor 
2 poor 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo 0/ehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page I ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 61 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xx-xxxx L16.2.6.5.1 Listing of Efficacy Endpoints (Observed Case) 
Secondary End2oints 
Test of Mycological Complete Satisfactory Almost Complete Complete or Almost 
Cure Clinical Clinical Therapeutic Complete 
Visit Cure Cure Cure Cure Thera2eutic Cure 
Day 141 No No Yes No No 
Day 281 N/A No Yes N/A N/A 
Day 365 Yes Yes Yes Yes Yes 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm 
L16.2.6.5.2 Listing of Efficacy Endpoints Using Canfield Evaluation 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Primary End2oint 
Complete 
Therapeutic 
Cure 
No 
N/A 
Yes 
Page 1 ofN 
Page 62 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
L16.2.6.5.4 Listing of Primary Efficacy Endpoints (Sensitivity Analysis) 
Sensitivi!,y Anal,}:'sis 1 Sensitivi!,y Anal,l'sis 2 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xx-xxxx Test of 
Cure 
Visit 
Day 141 
Day281 
Day 365 Per-Protocol Canfield Per-Protocol 
Evaluation Evaluation Evaluation 
No No No 
Yes Yes Yes 
Yes Yes Yes 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I-56 and Days 28I-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 281-336 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Canfield 
Evaluation 
No 
Yes 
Yes 
Page 1 ofN 
Page 63 of71 
Taro Pharmaceuticals U.S.A., Iuc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
L16.2.7.1 Listing of Adverse Events by treatment group 
Treatment Patient Body System I Treatment Start /End Relationship Action Other 
Group Randomization MedDRA Term I Area Date Severity to Study Outcome Taken Action SAE? 
Number AE Term Drug Taken 
Treatment Group A xx-xxxx Nervous system disorders I No yyyy-mm-dd I Mild Possible Recovered Dose None No 
Treatment Group B 
Treatment Group C Headache/ 
Headache yyyy-mm-dd 
Treatment Group A: Novexatin® 10% Topical Solution for Days I-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days I-56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281-336 
Created on: ddmmmyy hh:mm 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Not 
Changed 
Page 1 ofN 
Page 64 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
L16.2.7.2 Listing of Application Site Reactions 
Signs and Symptoms* 
Treatment Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Patient 
Randomization 
Number 
xxxx Visit Erythema 
3 0 
4 0 
5 0 
6 0 
7 0 Scalino-/ . . . D "" Stmgmg/ ErosiOn 
ryness Bumin 
0 0 1 
1 0 0 
0 0 1 
0 0 1 
0 0 1 
*Signs and symptoms: 0 =Absent; I =Mild; 2 =Moderate; 3 = Severe Edema 
(swelling) 
0 
0 
0 
0 
0 Pain Itching 
0 0 
0 0 
0 0 
2 2 
2 2 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281 -336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1 -56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/2!12018 • Taro Pharmaceuticals U.S.A., Inc. • Page 65 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C L16.2.7.3 Listing of Abnormal Physical Examination Results 
Patient 
Randomization 
Number 
xx-xxxx Visit System Result 
Visit4 Cardiovascular Abnormal (NCS) If Abnormal, provide 
comment 
xxxxxxxxxxxxxxxxx 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1 -56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1 -56 and Days 281 -336 
Created on: ddmmmyy hh:mm Page I ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 66 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C Novum Pharmaceutical Research Services 
Protocol/ Study No. NVXT 1404171442603 
L16.2.7.4 Listing of Positive Pregnancy Test Results 
Patient 
Randomization Visit Results 
Number 
xx-xxxx Visit4 Positive 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page 1 ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 67 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Treatment 
Group 
Treatment Group A 
Treatment Group B 
Treatment Group C L16.2.8.1 Listing of Clinical Laboratory Testing Results (Hematology) 
Patient 
Randomization Lab 
Number Visit Date Test SI Results SI Unit 
xx-xxxx 1 yyyy-mm-dd Hemoglobin XXX g/L 
3 yyyy-mm-dd Hemoglobin XXX g/L 
7 yyyy-mm-dd Hemoglobin XXX g/L Normal Range 
XXX, XXX 
XXX, XXX 
XXX, XXX 
Treatment Group A: Novexatin® 10% Topical Solution for Days 1-56 and Placebo (Vehicle) Topical Solution for Days 281 -336 
Treatment Group B: Novexatin® 10% Topical Solution for Days 1-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days 1-56 and Days 281 -336 
Created on: ddmmmyy hh:mm Page 1 ofN 
L16.2.8.2 Listing of Clinical Laboratory Testing Results (Chemistry) 
L16.2.8.3 Listing of Clinical Laboratory Testing Results (Urinalysis) 
3/2!/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 68 of71 
Taro Pharmaceuticals U.S.A., Inc. 
Novexatin 10% topical solution 
L16.2.8.4 Listing of Vital Signs Novum Pharmaceutical Research Services 
Protocol I Study No. NVXT 1404/71442603 
Treatment 
Group Patient 
Randomization Visit 
Number Systolic BP Diastolic BP Heart Rate Respiration Temperature Rate 
Treatment Group A 
Treatment Group B 
Treatment Group C xx-xxxx 1 
3 
5 
6 
7 (mmHg) (mmHg) 
120 70 
140 80 (beats/min) {breath/min} (F) 
84 18 98.6 
74 18 97.0 
Treatment Group A: Novexatin® I 0% Topical Solution for Days 1 -56 and Placebo (Vehicle) Topical Solution for Days 281-336 
Treatment Group B: Novexatin® 10% Topical Solution for Days l-56 and Days 281-336 
Treatment Group C: Placebo (Vehicle) Topical Solution for Days I-56 and Days 281-336 
Created on: ddmmmyy hh:mm Page I ofN 
3/21/2018 • Taro Pharmaceuticals U.S.A., Inc. • Page 69 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol I Study No. NVXT 1404/71442603 
10. APPENDICES 
Appendix A: Evaluation ofToenail Condition/appearance 
The number of toenails infected should be counted. The toenail, one of the two great toenails, 
that the investigator considers to be the most appropriate as the target toenail will be identified at 
Visit 2 and designated as the "target toenail" and used for all further evaluations. 
Evaluation of Toenail condition/appearance 
The overall appearance of the target toenail over time will be monitored during the study: 
Self-assessed by patients. The results of the self-assessment will be recorded by the patient 
before beginning therapy at Visit 2 and at all subsequent visits .. Patients will use a 5-point scale 
for target toenail appearance: 
I. Very Poor 
2. Poor 
3. Normal/acceptable 
4. Good 
5. Very good 
Assessed by Investigator. Investigators will rate the status of the target toenail before patient 
begins therapy at Visit 2 and at all subsequent clinic visits. Nail condition/appearance by 
investigator will be evaluated after nail trimming to the distal groove and before further 
trimming, if required, for the mycological evaluation. Investigators will use a 5-point scale target 
toenail appearance: 
1. Very Poor 
2. Poor 
3. Normal/acceptable 
4. Good 
5. Very good 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 70 of71 
NOVUM PHARMACEUTICAL RESEARCH SERVICES 
STATISTICAL ANALYSIS PLAN 
Novexatin 10% topical solution Protocol/ Study No. NVXT 1404/71442603 
Appendix B: Application Site Reactions 
Monitoring of local tolerability (inflammation) will be based upon established methods 
including observation of the area of administration and response scoring by the study 
personnel. Upon the visits to the clinical study site, each patient will be examined for signs of 
local inflammation and irritation that may be associated with the study products. If any such 
signs are identified, the response will be graded as follows: 
Signs and Symptoms: 
Erythema (redness) 
Scaling/Dryness 
Stinging/Burning 
Erosion 
Edema (swelling) 
Pain 
Itching 
Grading Scale: 
Absent 0 
Mild I (slight, barely perceptible) 
Moderate 2 (distinct presence) 
Severe 3 (marked, intense) 
Application site reactions will not be separately recorded as AEs since they are being 
captured at each visit for erythema, burning/stinging, erosion, edema, pain, itching or dryness 
unless the Investigator feels it is appropriate to do so. 
3/2112018 • Taro Pharmaceuticals U.S.A., Inc. • Page 71 of71 